Magneto-Optical Diagnosis Evaluated for Symptomatic Malaria
|
By LabMedica International staff writers Posted on 02 Mar 2021 |

Image: Malaria: Thick bloods smear showing ring-form trophozoites of Plasmodium vivax that are difficult to detect. Two ring-forms are arrowed (Photo courtesy of US Centers of Diseases Control and Prevention).
Malaria places a significant social and economic burden on many tropical developing countries, further undermining the potential for growth. Development of rapid, easy-to-use and low-cost malaria diagnostic methods, with high sensitivity and specificity, remains an urgent priority for tropical diseases.
Currently available methods to diagnose malaria include the inspection of blood smears using light microscopy (LM), rapid diagnostic tests (RDTs), and molecular methods, such as polymerase chain reaction (PCR) or other molecular techniques. A novel method, named rotating-crystal magneto-optical detection has been evaluated.
An international team of scientists led by those at the James Cook University (Smithfield, Australia) developed and tested the method called rotating-crystal magneto-optical detection (RMOD) on nearly 1,000 suspected malaria patients in a high-transmission area of Papua New Guinea. The novel method was compared with LM, using thick blood smears for parasite density quantification and real time PCR that employed a two-step protocol using a using a CFX96 Touch qPCR system (Bio-Rad Laboratories Pty., Ltd., Gladesville, Australia).
The team reported that compared to light microscopy, RMOD exhibits 82% sensitivity and 84% specificity to detect any malaria infection and 87% sensitivity and 88% specificity to detect Plasmodium vivax. This indicates that RMOD could be useful in P. vivax dominated elimination settings. Parasite density correlates well with the quantitative magneto-optical signal. Importantly, residual hemozoin present in malaria-negative patients is also detectable by RMOD, indicating its ability to detect previous infections.
Stephan Karl, PhD, a Senior Research Fellow and a corresponding author of the study, said, “Malaria is easily treated but it is actually hard to diagnose, and because of that there can be over-treatment, which we have seen can lead to the spread of drug-resistant malaria. Malaria parasites break down blood in such a way that heme molecules in the blood assemble themselves into organic crystallites containing magnetic iron, which is detected by the RMOD method.”
The authors concluded that they had carried out an extensive assessment of a promising novel method to diagnose malaria rapidly and at low cost in a high transmission setting and a population of symptomatic, suspected malaria cases in Papua New Guinea. The present study shows that in such a setting, the RMOD performs well in comparison to expert LM-based diagnosis, the most reliable reference method in their study. The study was published on February 12, 2021 in the journal Nature Communications.
Related Links:
James Cook University
Bio-Rad Laboratories
Currently available methods to diagnose malaria include the inspection of blood smears using light microscopy (LM), rapid diagnostic tests (RDTs), and molecular methods, such as polymerase chain reaction (PCR) or other molecular techniques. A novel method, named rotating-crystal magneto-optical detection has been evaluated.
An international team of scientists led by those at the James Cook University (Smithfield, Australia) developed and tested the method called rotating-crystal magneto-optical detection (RMOD) on nearly 1,000 suspected malaria patients in a high-transmission area of Papua New Guinea. The novel method was compared with LM, using thick blood smears for parasite density quantification and real time PCR that employed a two-step protocol using a using a CFX96 Touch qPCR system (Bio-Rad Laboratories Pty., Ltd., Gladesville, Australia).
The team reported that compared to light microscopy, RMOD exhibits 82% sensitivity and 84% specificity to detect any malaria infection and 87% sensitivity and 88% specificity to detect Plasmodium vivax. This indicates that RMOD could be useful in P. vivax dominated elimination settings. Parasite density correlates well with the quantitative magneto-optical signal. Importantly, residual hemozoin present in malaria-negative patients is also detectable by RMOD, indicating its ability to detect previous infections.
Stephan Karl, PhD, a Senior Research Fellow and a corresponding author of the study, said, “Malaria is easily treated but it is actually hard to diagnose, and because of that there can be over-treatment, which we have seen can lead to the spread of drug-resistant malaria. Malaria parasites break down blood in such a way that heme molecules in the blood assemble themselves into organic crystallites containing magnetic iron, which is detected by the RMOD method.”
The authors concluded that they had carried out an extensive assessment of a promising novel method to diagnose malaria rapidly and at low cost in a high transmission setting and a population of symptomatic, suspected malaria cases in Papua New Guinea. The present study shows that in such a setting, the RMOD performs well in comparison to expert LM-based diagnosis, the most reliable reference method in their study. The study was published on February 12, 2021 in the journal Nature Communications.
Related Links:
James Cook University
Bio-Rad Laboratories
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







